Requires disclosure of information concerning non-invasive prenatal screening for chromosomal abnormalities including the benefits and limitations of non-invasive prenatal testing, the difference between non-invasive prenatal testing and prenatal diagnostic testing, and current recommendations from the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine, and the American College of Medical Genetics and Genomics (ACMG).

New York State Senate Bill S00011 requires healthcare providers to give pregnant individuals clear, written information about non-invasive prenatal screenings for chromosomal abnormalities. This includes explaining the benefits and limitations of these tests, how they differ from diagnostic tests, and current recommendations from professional medical organizations.

The bill received unanimous support in the Senate, indicating strong bipartisan agreement on the importance of informed consent in prenatal care. Legislators emphasized the necessity of providing clear information to patients about non-invasive prenatal screenings.

There is no recorded opposition to the bill during committee discussions or voting. However, potential concerns about the implementation and effectiveness of the required disclosures may arise in future discussions.